New Business Startup Looks To Use DNA Technology For Diseases
On behalf of The Law Office of Lynnette Ariathurai, A Professional Corporation posted in Business Formation & Planning on Thursday, August 13, 2015.
Genetics play a significant role in determining the likelihood of contracting many types of diseases. In the past, there seemed to be little that a person in California could do about one's genetics. However, new biotechnological advancements have changed this dynamic, allowing the possible manipulation of genes. One new business startup is attempting to capitalize on this technology while also helping to fight disease.
The company, Editas, just recently raised $120 million from investors in order to develop ways to utilize the new technology, which allows scientists to edit human genes more easily. CRISPR-Cas9, the new biotechnology tool, could eventually enable scientists to pinpoint a specific gene that may be faulty in order to exchange it with another more preferable gene. The newly raised investment funds are aimed to assist in the continued study of the new biotechnology.
Scientists have reportedly already utilized the new technology in order to replace defective mice DNA, resulting in curing the mice of various genetic disorders. Other researchers were able to use the technology to edit DNA of non-viable human embryos, which are embryos that would never be able to develop into people. These researchers were also able to manipulate a gene that would usually cause a rare blood disorder.
On the other hand, just like any new business startup in California, Edita will need to make sure its business model complies with applicable rules and regulations. This is particularly important in the biotechnology and medical fields, which are some of the most regulated industries. However, no matter what industry a new company is attempting to enter, it is important to be knowledgeable of the laws which apply.
Source: businessinsider.com, "A startup that wants to make it easier to tweak our genes just got $120 million from investors including Bill Gates", Lydia Ramsey, Aug. 10, 2015